Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: soozathelooza who wrote (22)	3/26/1998 6:48:00 PM
From: WHL	Respond to of 946

Here's CTIC's new lead drug. It's already well down the road. From a previous post: "I think people are missing the major potential drug in CT-2584. I read from New Scientist ( newscientist.com ) in the 29NOV, 1997 issue that this drug bypasses the usual multidrug resistant mechanism(MDM) where the survivor cells learn to activate cellular pumps that pump out toxic materials at 100 times the rate of normal cells." The net result of bypassing MDM is that the tumor is unable to pump out the toxic materials targeting its destruction.